SecBot SecBot
SECBOTREPLAY Home › Report › ARVN

ARVN · Arvinas (ARVN) filed an 8-K announcing the departure of Chief Medical…

ARVINAS, INC. · 8-K filed Jun 22, 2026 at 16:10 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 22, 2026 at 16:10 ET

Arvinas (ARVN) filed an 8-K announcing the departure of Chief Medical Officer Dr. Noah Berkowitz, effective July 3, 2026, with a search for a replacement underway. The departure is described as voluntary to pursue other opportunities, with standard severance including 9 months base salary and accelerated vesting of RSUs through May 9, 2027. This is a routine officer departure for a biotech company, the CMO role is important but not a CEO/CFO-level exit, and the filing lacks any financial data or guidance changes.

  • Chief Medical Officer Dr. Noah Berkowitz departing July 3, 2026
  • Departure described as voluntary to pursue other opportunities
  • Search for replacement CMO has begun
  • Severance: 9 months base salary continuation + up to 9 months health coverage

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access